VANCOUVER, British Columbia — November 28, 2025 — Leads & Copy — Avricore Health Inc. (TSXV: AVCR) has announced that its HealthTab™ technology is being deployed in a new pilot program by Barts Health NHS Trust. This initiative, in collaboration with UCL Partners and the British Heart Foundation (BHF), aims to deliver inclisiran, a cholesterol-lowering injection, through community pharmacies.
The pilot is supported by a £198,000 grant from the BHF and is designed to decentralize cardiovascular therapy delivery, reduce the burden on hospitals, and support individuals with long-term conditions in their local communities. This program builds upon the ELoPE-CVD initiative, which focuses on expanding preventive heart care access and optimizing lipid management for high-risk patients.
One of the key advancements facilitating this program is the integration of HealthTab™ with the Ortus-iHealth platform. This integration allows pharmacy-generated results to be directly accessible within hospital clinical systems. This connectivity complements HealthTab’s existing integration with the NHS App, ensuring data is readily available to both specialist clinicians and patients through established NHS digital pathways.
Rodger Seccombe, CEO of Avricore Health, stated that bringing inclisiran injections into community pharmacies is an important milestone for cardiovascular care, and HealthTab is proud to facilitate this. He added that by integrating with the Ortus platform and linking into specialist teams, HealthTab is enabling pharmacies to play a meaningful role in secondary prevention and long-term condition management.
The pilot program will evaluate the effectiveness of community pharmacies in several key areas:
- Administering inclisiran injections, traditionally given in hospital lipid clinics.
- Initiating therapy sooner for patients awaiting specialist care.
- Identifying at-risk patients through pharmacy-based cholesterol testing via HealthTab™.
- Providing structured follow-up and monitoring as part of a long-term lipid management pathway.
The NHS has set a goal to prevent up to 150,000 heart attacks, strokes, and cases of dementia over the next decade by improving the detection and management of high-risk conditions, including high cholesterol. This includes increasing the role of community pharmacies in managing long-term conditions and integrating them into shared digital records.
The deployment within a major cardiovascular program highlights HealthTab’s role as a trusted platform for community-based diagnostics and workflow support, spanning both primary and secondary prevention. The integration with Ortus enhances the platform’s value by connecting HealthTab™ to hospital clinical systems, moving it beyond diagnostics into integrated care-team support.
Additionally, the platform’s ability to support therapy initiation, administration, and monitoring expands HealthTab’s relevance and value, positioning community pharmacies as key partners in cardiovascular condition management.
HealthTab™ aims to meet high standards for analytical performance and reliability. Through a partnership with CEQAL Inc., HealthTab operates a comprehensive quality management program, mirroring the standards of accredited clinical laboratories. This includes centralized lot monitoring of reagents, internal quality-control procedures, regular external quality-assessment events, and expert oversight services to ensure the accuracy and traceability of results to recognized reference standards.
Rodger Seccombe, CEO of Avricore Health. Contact: info@avricorehealth.com
Source: Avricore Health Inc.
